Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2020 Filed Mar 23, 2020 20:30 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 11,120 | $0.33 | $3,669.60 |
DisclosureSEC source: 0001209191-20-020638 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 2,700 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 2,700 | $25.56 | $69,012.00 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 2,700 | $4.07 | $10,989.00 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,300 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 12,300 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 2,979 | $25.03 | $74,564.37 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $24.54 to 25.46, inclusive. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 9,321 | $24.15 | $225,102.15 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $23.52 to 24.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:30 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 12,300 | $4.07 | $50,061.00 |
DisclosureSEC source: 0001209191-20-018103 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 5,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,000 | $33.55 | $167,750.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 5,000 | $0.84 | $4,200.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 80,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 12,200 | $34.01 | $414,922.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.00 to 34.06, inclusive. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 67,800 | $33.49 | $2,270,622.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.00 to 33.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 80,000 | $0.84 | $67,200.00 |
DisclosureSEC source: 0001209191-20-011949 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-011948 · doc4.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,600 Underlying: Common Stock · 7,400 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 6,600 | $33.53 | $221,298.00 |
DisclosureSEC source: 0001209191-20-011948 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.07 to 33.97, inclusive. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 800 | $32.85 | $26,280.00 |
DisclosureSEC source: 0001209191-20-011948 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,279 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.75 to 32.95 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:15 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,400 | $6.32 | $46,768.00 |
DisclosureSEC source: 0001209191-20-011948 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-011074 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 55,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-011074 · doc4.xml · derivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 80,000 | $33.00 | $2,640,000.00 |
DisclosureSEC source: 0001209191-20-011074 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 55,000 | $0.84 | $46,200.00 |
DisclosureSEC source: 0001209191-20-011074 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 25,000 | $0.84 | $21,000.00 |
DisclosureSEC source: 0001209191-20-011074 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · derivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,000 Underlying: Common Stock · 7,400 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,900 | $33.21 | $129,519.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.75 to 33.66, inclusive. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,500 | $32.18 | $112,630.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,579 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.74 to 32.65, inclusive. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,400 | $6.32 | $46,768.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · derivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,400 Underlying: Common Stock · 18,500 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 18,500 | $31.38 | $580,530.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.93 to 31.72 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 18,500 | $6.32 | $116,920.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC |
Taylor Stacy LSVP and General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009868 · doc4.xml · derivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009861 · doc4.xml · derivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-02-13 F5 · derivative.exercise_date: The options will vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,120 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-009861 · doc4.xml · derivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,280 Underlying: Common Stock · 11,120 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 11,120 | $31.56 | $350,947.20 |
DisclosureSEC source: 0001209191-20-009861 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.02 to 31.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 11,120 | $0.33 | $3,669.60 |
DisclosureSEC source: 0001209191-20-009861 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC |
SANG CHARLESSVP, Clinical Diagnostics
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009863 · doc4.xml · derivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC |
ZOLTNERS ANDRIS ADirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009864 · doc4.xml · derivative · entry 1 ZOLTNERS ANDRIS A · CIK 0001780665 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
LO FRANCISChief People Officer
|
GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009872 · doc4.xml · derivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
RUBINSTEIN JULIEPresident
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009873 · doc4.xml · derivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC |
HILL NANCY LOUISESVP, Operations
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009860 · doc4.xml · derivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
ROBINS HARLAN SChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009870 · doc4.xml · derivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
GRIFFIN MICHELLE RENEEDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009874 · doc4.xml · derivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
Cohen Chad MChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009871 · doc4.xml · derivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
HERSHBERG ROBERTDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009867 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
Pellini Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009869 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
BENZENO SHARONSVP, Drug Discovery
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009866 · doc4.xml · derivative · entry 1 BENZENO SHARON · CIK 0001780854 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
BALDO LANCEChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009862 · doc4.xml · derivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
Conroy Kevin TDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009859 · doc4.xml · derivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC |
DOBMEIER ERICDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009858 · doc4.xml · derivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.